Reductions increased to 70% after a second dose of the Pfizer vaccine, data from the UK Covid-19 Infection Survey show. Not enough people had yet received two doses of the AstraZeneca vaccine to assess this.
Friday, April 23, 2021
Covid-19: Infections fell by 65% after first dose of AstraZeneca or Pfizer vaccine, data show
Infections of SARS-CoV-2 fell by 65% after a first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines, preliminary results from a large UK surveillance study indicate.
Monday, April 19, 2021
Nasa successfully flies small helicopter on Mars
The drone, called Ingenuity, was airborne for less than a minute, but Nasa is celebrating what represents the first powered, controlled flight by an aircraft on another world.
https://www.bbc.com/news/science-environment-56799755
Thursday, April 15, 2021
Denmark continues vaccine rollout without the AstraZeneca vaccine
The National Board of Health paused the use of the COVID-19 vaccine from AstraZeneca on March 11, 2021. This was done on the basis of worrying signals from the ongoing safety monitoring of the COVID-19 vaccines. The vaccination program has since then continued with the vaccines from Pfizer / BioNTech and Moderna.
Sunday, April 11, 2021
Hard choices emerge as link between AstraZeneca vaccine and rare clotting disorder becomes clearer
What was a worrisome suspicion 4 weeks ago is now widely accepted: The AstraZeneca COVID-19 vaccine can, in very rare cases, cause a disorder characterized by dangerous blood clots and low platelet counts. In Europe, at least 222 suspected cases have been reported among 34 million people who have received their first dose of the vaccine. More than 30 have died.
Tuesday, March 2, 2021
Bharat Biotech Announces Phase 3 Results of COVAXIN®: India’s First COVID-19 Vaccine Demonstrates Interim Clinical Efficacy of 81%
Bharat Biotech, a global leader in vaccine innovation, developing vaccines for infectious diseases, today announced the first interim analysis of its BBV152 (COVAXIN®). The whole virion inactivated COVID-19 vaccine candidate demonstrated an interim vaccine efficacy of 81% in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research.
Friday, February 26, 2021
FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The EUA allows the Janssen COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years of age and older.
Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend Emergency Use Authorization (EUA) for the Company’s single-shot COVID-19 vaccine candidate for adults 18 and older, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. The vote was based on a totality of scientific evidence provided by the Company, including efficacy and safety data from the Phase 3 ENSEMBLE trial.
Subscribe to:
Posts (Atom)